Source - Alliance News

Hikma Pharmaceuticals PLC - London-based generic drugmaker - Receives preliminary approval from the US Federal Trade Commission for its planned acquisition of Custopharm Inc. Back in September, Hikma agreed to buy the California, US-based generic injectable products company for a total of up to $425 million.

Current stock price: 2,068.00 pence, down 0.6% on Wednesday

12-month change: down 13%

Copyright 2022 Alliance News Limited. All Rights Reserved.

Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJBell logo

Related Charts

Hikma Pharmaceuticals PLC (HIK)

+38.00p (+2.02%)
delayed 18:10PM